Clinical Trials Logo

Leukemia, Monocytic, Acute clinical trials

View clinical trials related to Leukemia, Monocytic, Acute.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05566054 Recruiting - Newly Diagnosed Clinical Trials

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy

NCT ID: NCT05313958 Recruiting - Pediatric AML Clinical Trials

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

SCCLG-M5
Start date: December 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3 positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.

NCT ID: NCT01146210 Recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: October 2009
Phase: N/A
Study type: Observational

This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to Fanconi anemia in patients with acute myeloid leukemia.